Moxonidine: A new and versatile antihypertensive

Journal of Cardiovascular Pharmacology

Volumn 35, Issue SUPPL. 4, 2000, Pages

  Messerli, F ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Antihypertensive therapy; Essential hypertension; Imidazoline receptor; Insulin resistance; Metabolic syndrome; Moxonidine; Sympathetic nervous system

Indexed keywords

ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; MOXONIDINE; NEW DRUG; NIFEDIPINE; NORADRENALIN; RENIN;

ADRENERGIC SYSTEM; ARTERIAL PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HUMAN; HYPERTENSION; INSULIN RESISTANCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYMPATHETIC TONE; VASCULAR RESISTANCE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; IMIDAZOLES; SYMPATHETIC NERVOUS SYSTEM;

EID: 0033652999     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200000004-00007     Document Type: Review

References (40)

1. The effects of environmental and lifestyle factors on blood pressure and the intermediary role of the sympathetic nervous system
2. Excess catecholamines and the metabolic syndrome: Should central imidazoline receptors be a therapeutic target?
3. Early association of sympathetic overactivity, hypertension, insulin resistance, and coronary risk
4. Association of tachycardia with morbidity and mortality: Pathophysiological considerations
5. Role of parasympathetic inhibition in the hyperkinetic type of hypertension
6. Elevated sympathetic nerve activity in borderline hypertensive humans
7. Sympathetic activity, blood pressure variability and end organ damage in hypertension
8. Banting Lecture 1988. Role of insulin resistance in human disease
9. Syndrome X: 6 Years later
10. Hypertension and associated metabolic abnormalities - The role of insulin resistance and the sympathoadrenal system
11. Hyperinsulinaemia, upper body obesity, and cardiovascular risk factors
12. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia, and atherosclerotic vascular disease
13. Hypothesis. The hemodynamic link between insulin resistance and hypertension
14. Blood pressure, stroke and coronary heart disease. Part 2: Short term reduction in blood pressure: Overview of randomized drug trials in their epidemiological context
15. General pharmacology of the novel centrally acting antihypertensive agent moxonidine
16. Moxonidine: A second-generation antihypertensive agent
17. 1-imidazoline receptors in the rostral ventrolateral medulla
18. Centrally acting antihypertensives: A renaissance of interest. Mechanisms and haemodynamics
19. Clinical pharmacokinetics of moxonidine
20. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients
21. The pharmacokinetics of moxonidine
22. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension
23. Haemodynamic and neurohormonal effects of moxonidine in patients with essential hypertension
24. Demonstration of hypertrophy regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine
25. Hypertensive coronary microcirculation - Effects of the imidazoline-receptor-agonist moxonidine
26. 1 receptor agonist moxonidine in patients with mild to moderate essential hypertension
27. Wirksamkeit und Vertragichkeit des neuen zentralwirksamen antihypertensivums moxonidin im vergleich zu enalapril
28. Moxonidin vs. captopril bei leicher bis mittelschwerer hypertonie. Doppelblindstudie zur wirksamkeit und vertraglichkeit
29. 24-Hour blood pressure profiles in patients with mild-to-moderate hypertension: Moxonidine versus captopril
30. A double-blind comparison of moxonidine and atenolol in the management of patients with mild to moderate hypertension
31. The treatment of hypertensive patients with a calcium antagonist or moxonidine: A comparison
32. Moxonidine and hydrochlorothiazide in combination: A synergistic antihypertensive effect
33. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension. Results of the TOPIC (Trial Of Physiotens In Combination) Study
34. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
35. 1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives
36. Aspects of tolerability of centrally acting anti-hypertensive drugs
37. Safety and tolerability of moxonidine in the treatment of hypertension
38. Effects of agmatine and moxonidine on glucose metabolism: An integrated approach to pathophysiological mechanisms in cardiovascular metabolic disorders
39. Oral presentation
40. Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial